Citigroup’s Envoy Medical COCH Stock Holding History

Citigroup’s Portfolio COCH Stock Details COCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$143	Buy	215 +214	+21,400%	+$146	﹤0.01%	5595
2025 Q4	$1	Sell	1 -70	-99%	-$55	﹤0.01%	5963
2025 Q3	$55	Buy	+71	New	+$96	﹤0.01%	5846

Other funds holding COCH

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCA

DSG Capital Advisors Edina, Minnesota $625M AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

ACP

Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CBU

CIBC Bancorp USA Chicago, Illinois $74.4B AUM

Citigroup's COCH Position: Q1 2026 in Review

Citigroup increased its Envoy Medical (COCH) stake by 21,400% in Q1 2026, buying an estimated $146 and bringing the position to 215 shares worth $143. The position accounts for ﹤0.01% of the portfolio, ranked #5595.

Citigroup first reported a position in COCH in Q3 2025 and has held it in 3 quarters since. 33 funds tracked by Wall St. Rank hold COCH as of Q1 2026.

Citigroup held 215 shares of Envoy Medical worth $143 as of Q1 2026.
Citigroup bought 214 Envoy Medical shares in Q1 2026, an estimated $146.
Envoy Medical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5595 holding.
Citigroup first reported a position in Envoy Medical in Q3 2025 and has held it in 3 quarters since.
33 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.